Patents Examined by Michael Allen
-
Patent number: 11945879Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy chain/light chain mispairing.Type: GrantFiled: August 18, 2020Date of Patent: April 2, 2024Assignees: Jean Kadouche, Centre National de la Recherche Scientifique, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, University of LausanneInventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
-
Patent number: 11918649Abstract: Provided herein are PD-L1 binding molecules comprising or conjugated to a toxin, e.g. a Shiga toxin A Subunit derived polypeptide. In some embodiments, the PD-L1 binding molecules are cytotoxic. In some embodiments, the PD-L1 binding molecules are capable of delivering a CD8+ T-cell epitope to an MHC class molecule inside a PD-L1 positive cell. The PD-L1 binding molecules described herein have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells); for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving PD-L1 expressing cells (e.g., PD-L1 positive tumor cells or immune cells).Type: GrantFiled: September 18, 2020Date of Patent: March 5, 2024Assignee: Molecular Templates, Inc.Inventors: Eric Poma, Hilario Ramos, Erin Willert, Richard Shimkets, Crystal Jackson, Thomas Vincent
-
Patent number: 11912773Abstract: Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.Type: GrantFiled: May 12, 2020Date of Patent: February 27, 2024Assignee: Genentech, Inc.Inventors: J. Michael Elliott, Justin Scheer
-
Patent number: 11883495Abstract: Provided are anti-CD47 antibodies and fragments thereof. The antibodies and fragments thereof specifically bind to the CD47 protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and atherosclerosis are also provided.Type: GrantFiled: May 10, 2021Date of Patent: January 30, 2024Assignee: Lepu Biopharma Co., Ltd.Inventors: Wenci Gong, Yiwei Tou
-
Patent number: 11873342Abstract: Provided are antibodies or fragment thereof having binding specificity to the human chemokine (C—C motif) receptor 8 (CCR8) protein. These antibodies are capable of binding to CCR8 at high affinity and can mediate antibody-dependent cellular cytotoxicity (ADCC).Type: GrantFiled: March 2, 2022Date of Patent: January 16, 2024Assignee: LaNova Medicines LimitedInventors: Runsheng Li, Wentao Huang
-
Patent number: 11840577Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.Type: GrantFiled: July 30, 2020Date of Patent: December 12, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Meike Hutt, Felix Unverdorben, Sebastian Bunk, Dominik Maurer, Martin Hofmann, Gabriele Pszolla, Sara Yousef, Claudia Wagner, Frank Schwoebel, Heiko Schuster
-
Patent number: 11840553Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.Type: GrantFiled: June 22, 2018Date of Patent: December 12, 2023Assignee: Novimmune SAInventors: Krzysztof Masternak, Nicolas Fischer, Francois Rousseau, Elie Dheilly, Marie Kosco-Vilbois
-
Patent number: 11833202Abstract: A method of treating cancer, killing metastatic cancer cells, killing potentially-malignant neoplasm cells and/or preventing cancer metastasis comprises administering to a subject a composition comprising an anti-AGE antibody. A method of diagnosing metastatic cancer comprises detecting an immune complex comprising an anti-AGE antibody bound to a cell expressing an AGE modification.Type: GrantFiled: February 16, 2017Date of Patent: December 5, 2023Assignee: SIWA CorporationInventor: Lewis S. Gruber
-
Patent number: 11814440Abstract: The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen.Type: GrantFiled: November 8, 2016Date of Patent: November 14, 2023Assignees: The Children's Hospital of Philadelphia, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: John M. Maris, Kristopher R. Bosse, Dimiter Dimitrov, Zhongyu Zhu, Dontcho V. Jelev
-
Patent number: 11766479Abstract: Disclosed herein are antibodies against ENPP3 and uses thereof, specifically monoclonal antibodies against ENPP3, bispecific antibodies against ENPP3 and CD3, nucleic acids including nucleotide sequences encoding the antibodies, vectors including the nucleic acids, and host cell including the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and conjugates including the antibodies, and therapeutic methods for using the antibodies.Type: GrantFiled: July 27, 2022Date of Patent: September 26, 2023Assignee: Zhejiang Shimai Pharmaceutical Co., Ltd.Inventors: Zuoxiang Xiao, Jiaping Peng, Dongwen Zhou, Wei Zhou
-
Patent number: 11753481Abstract: The present invention relates to bispecific antibodies which bind to human carcinoembryonic antigen CEACAM5 and human CD47. In addition, the present invention relates to polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further relates to methods for selecting and producing such antibodies and to methods of using such antibodies in the treatment of diseases. The invention also relates to the therapeutic use of the bispecific antibodies in monotherapy and in combination therapy.Type: GrantFiled: December 17, 2021Date of Patent: September 12, 2023Assignee: LAMKAP BIO BETA LTDInventors: Vanessa Buatois, Dirk Hose, Anja Seckinger
-
Patent number: 11723971Abstract: The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.Type: GrantFiled: December 4, 2019Date of Patent: August 15, 2023Assignees: JN Biosciences, LLC, Abmuno Therapeutics, LLCInventors: J. Yun Tso, Naoya Tsurushita, Omar Duramad
-
Patent number: 11723972Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.Type: GrantFiled: September 17, 2019Date of Patent: August 15, 2023Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional De Investigaciones Científicas y Técnicas (CONICET), Fundacion SalesInventors: Margaret Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
-
Patent number: 11707522Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Tn antigen or sTn antigen. The compositions disclosed herein include isolated antibody or functional fragments thereof that binds to Tn antigen or sTn antigen and polynucleotides encoding the heavy chain and/or a light chain variable domains of such antibody or functional fragment. The invention also provides methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a localizing agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.Type: GrantFiled: October 12, 2018Date of Patent: July 25, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Godfrey Jonah Anderson Rainey, Wolfgang Walter Scholz, Ritsuko Sawada
-
Patent number: 11692041Abstract: The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.Type: GrantFiled: July 15, 2016Date of Patent: July 4, 2023Assignee: UCB BIOPHARMA SRLInventors: Helene Margaret Finney, Stephen Edward Rapecki, Kerry Louise Tyson, Michael John Wright
-
Patent number: 11685773Abstract: The present invention relates to a method for producing a population of 20 or more nucleic acids, each encoding at least one protein comprising at least one immunoglobulin variable domain having a rabbit-derived CDR3 amino acid sequence embedded in essentially human framework sequences, as well as to a population of nucleic acids and a population of proteins relates thereto and uses thereof.Type: GrantFiled: April 29, 2016Date of Patent: June 27, 2023Assignees: ABCHECK s.r.o., CHARLES RIVER LABORATORIES, INC.Inventors: Jacob E. Gunn Glanville, Vera Molkenthin, Remko Albert Griep, Ahmad Trad, Peter Milovnik, Volker Lang
-
Patent number: 11672859Abstract: The present application provides a recombinant fusion protein containing an anti-PD-L1 antibody or an antibody fragment thereof, with each paratope of the anti-PD-L1 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain variable region or a light chain variable region constituting the paratope, wherein the recombinant fusion protein can bind to CD47, PD-L1 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over-expression of CD47 and/or PD-L1 using the recombinant fusion protein.Type: GrantFiled: October 7, 2021Date of Patent: June 13, 2023Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.Inventors: Wenzhi Tian, Song Li
-
Patent number: 11672858Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: GrantFiled: December 19, 2019Date of Patent: June 13, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Anne Freimoser-Grundschober, Thomas Hofer, Ralf Hosse, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umaña, Inja Waldhauer, Wolfgang Richter, Alexander Knaupp, Halina Trochanowska
-
Patent number: 11648309Abstract: The application discloses method of treatment of cancer utilizing a linear or substantially linear epitope on netrin-1 that likely corresponds to the specific binding region of netrin-1 to receptor, in particular of the UNC5 class, especially UNC5B and UNC5A, or alternatively corresponds to a region nearby the specific binding region of netrin-1 to receptor that when bound to an antibody prevents netrin-1/receptor interaction. This determination of a linear epitope allows for the production of antibodies binding to netrin-1 and interfering with netrin-1/receptor interaction, thereby inducing apoptosis or cell death of tumour cells expressing or overexpressing netrin-1 and at least one netrin-1 receptor, owing the fact that this interaction inhibits netrin-1 binding to a receptor and the multimerization of the receptor. The application also discloses a murine monoclonal antibody directed against this epitope and various humanized forms thereof.Type: GrantFiled: October 18, 2019Date of Patent: May 16, 2023Assignee: NETRIS PHARMAInventors: Jean-Guy Delcros, Yann Dean
-
Patent number: 11638744Abstract: A method for suppression of progress of, suppression of recurrence of and/or treatment of cancer, by administering an Allergin-1 antagonist in a therapy of a cancer patient with insufficient therapeutic efficacy by a tumor immunotherapeutic agent, or a cancer therapy in combination with an anti-cancer drug.Type: GrantFiled: September 2, 2016Date of Patent: May 2, 2023Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro Shibayama, Hiroshi Arima, Takuya Simbo